One of Science Corporation’s patients in France recently finished reading a 300-page novel. Before PRIMA, she had lost her central vision entirely.
Science Corporation announced on July 22, 2026, the European commercial launch of PRIMA — the first and only treatment shown in clinical trials to restore functional central vision to patients with geographic atrophy caused by age-related macular degeneration, a leading cause of irreversible blindness affecting more than five million people globally.
PRIMA has received a CE mark under the European Union Medical Device Regulation from DEKRA, authorising its commercial availability across 30 European countries. First commercial procedures are expected to begin in Germany as early as September.
How it works
The system has two components. The first is a small wireless chip implanted beneath the retina in a one-hour outpatient procedure. The second is a pair of specialised AR glasses that the patient wears afterwards.
The glasses project near-infrared light to the implant, which converts it into electrical stimulation signals. A zoom-in feature provides patients with the ability to magnify letters. The implant has an ultra-thin profile and integrates wirelessly — there are no cables, no external processors, and no headset. From the outside, a patient using PRIMA looks like someone wearing an ordinary pair of glasses.
The implant was placed under the atrophic macula without a decline in mean existing natural vision — an important clinical detail meaning the procedure does not risk the remaining peripheral vision patients retain.
What the clinical trials showed
80% of patients achieved significant prosthetic visual acuity improvements of at least logMAR 0.2, equivalent to 10 letters on the ETDRS chart, at 12 months. The results were published by the New England Journal of Medicine — one of medicine’s most authoritative publications — lending the trial data a level of credibility that investor-backed press releases rarely carry on their own.
Geographic atrophy destroys the light-sensitive cells at the back of the eye, making reading and recognising faces progressively impossible. There is currently no treatment that reverses this damage. PRIMA does not reverse it — it bypasses it, using the implant to stimulate the remaining retinal cells that the disease has not yet reached.
The company behind it
Science Corporation was founded by Max Hodak, a Neuralink cofounder and former president who left the Elon Musk-backed brain interface company in 2021. Science acquired Pixium Vision, the French company that developed PRIMA, in 2024 and continued preparing the technology for regulatory approval and commercial production. The company has raised approximately $490 million in total capital.
Science Corporation is currently in discussion with European healthcare providers over reimbursement. Each treatment is expected to cost hundreds of thousands of dollars. That price point means PRIMA will initially serve patients in healthcare systems where the cost can be absorbed through insurance or national health coverage — Germany first, with other European markets to follow.
A US path is also open. The FDA has granted Science Corporation Humanitarian Use Device designations for two rare causes of blindness, providing an expedited route toward US marketing approval, though no US launch date has been set.
The AR angle
PRIMA sits at the intersection of neuroscience, ophthalmology and augmented reality in a way that most AR coverage misses entirely. The glasses are not a consumer device, a productivity tool, or a gaming accessory. They are medical equipment whose function depends entirely on the AR layer — without the glasses projecting near-infrared light to the implant, the implant does nothing.
It is a reminder that the most consequential AR applications may not be the most visible ones. Reading a 300-page novel after losing your central vision is not a feature. It is, for the person holding the book, everything.